ERBB2 and breast carcinoma: This study showed that 15.3% of patients with HER2-positive breast carcinoma who received adjuvant trastuzumab therapy presented with cardiotoxicity, which resulted in treatment suspension and ultimately permanent treatment interruption in most of these cases.